Agomelatine versus Sertraline: An Observational, Open-labeled and 12 Weeks Follow-up Study on Efficacy and Tolerability
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: In this open-labeled, 12 weeks follow-up study, we aimed to compare the efficacy and tolerability of agomelatine with sertraline Methods: The outpatients of adult psychiatry clinic who have a new onset of depression and diagnosed as ‘major depressive episode’ by clinician according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition and prescribed agomelatine (25 mg/day) or sertraline (50 mg/day) were included in the study. Results: The decline of mean Montgomery-Asberg Depression Rating Scale (MADRS) scores of agomelatine group was significantly higher than the sertraline group at the end of 2nd week; however, the difference was not significant at the end of 3 months. Mean Clinical Global Impression-Improvement scale (CGI-I) scores of agomelatine group was lower than sertraline group at first week. Mean CGI-Severity scale and CGI-I scores were favour to sertraline group at the end of the study. Remission rates were 46.7% for sertraline group and 33.3% for agomelatine group while response rates were 76.7% for both groups. Any patient from agomelatine group dropped-out due to adverse effects. The amount of side effects was also less with agomelatine. Conclusion: Agomelatine has a rapid onset efficacy on depressive symptoms and this can be beneficial for some critical cases. Considering MADRS scores, agomelatine seems to have similar efficacy with sertraline but we also point the need for long term studies since CGI scores were favour to sertraline group at the end of the study. Agomelatine has a favourable tolerability profile both in terms of discontinuation and the amount of side effects compared to sertraline.
Abstract
Objective: In this open-labeled, 12 weeks follow-up study, we aimed to compare the efficacy and tolerability of agomelatine with sertraline Methods: The outpatients of adult psychiatry clinic who have a new onset of depression and diagnosed as ‘major depressive episode’ by clinician according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition and prescribed agomelatine (25 mg/day) or sertraline (50 mg/day) were included in the study. Results: The decline of mean Montgomery-Asberg Depression Rating Scale (MADRS) scores of agomelatine group was significantly higher than the sertraline group at the end of 2nd week; however, the difference was not significant at the end of 3 months. Mean Clinical Global Impression-Improvement scale (CGI-I) scores of agomelatine group was lower than sertraline group at first week. Mean CGI-Severity scale and CGI-I scores were favour to sertraline group at the end of the study. Remission rates were 46.7% for sertraline group and 33.3% for agomelatine group while response rates were 76.7% for both groups. Any patient from agomelatine group dropped-out due to adverse effects. The amount of side effects was also less with agomelatine. Conclusion: Agomelatine has a rapid onset efficacy on depressive symptoms and this can be beneficial for some critical cases. Considering MADRS scores, agomelatine seems to have similar efficacy with sertraline but we also point the need for long term studies since CGI scores were favour to sertraline group at the end of the study. Agomelatine has a favourable tolerability profile both in terms of discontinuation and the amount of side effects compared to sertraline.
참고문헌 (26)
- Loo H, "Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C)antagonist, in the treatment of major depressive disorder:a placebo-controlled dose range study", Int Clin Psychopharmacol, 17, pp.239~247 (2002)
- Goodwin GM, "Clinical studies on the efficacy of agomelatine on depressive symptoms", CNS Drugs, 23(Suppl 2), pp.35~39 (2009)
- Olié JP, "Efficacy of agomelatine, a MT1", MT2receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder, 2007, pp.10, 661~673
- Guaiana G, "Agomelatine versus other antidepressive agents for major depression", Cochrane Database Syst Rev, (12), pp.CD008851~ (2013)
- Demyttenaere K, "A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline", CNS Spectr, 18, pp.163~170 (2013)
- Shu L, "Comparable efficacy and safety of 8weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder", Asian J Psychiatr, 8, pp.26~32 (2014)
- Corruble E, "Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial", Int J Neuropsychopharmacol, 16, pp.2219~2234 (2013)
- Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
- Torun F, "The reliability and validity of Montgomery-Asberg depression rating scale for Turkish version", 3P Dergisi, 10, pp.319~330 (2002)
- Busner J, "The clinical global impressions scale:applying a research tool in clinical practice", Psychiatry (Edgmont), 4, pp.28~37 (2007)
- Lingjaerde O, "The UKU Side Effect Rating Scale: A new comprehensive rating scale for psyhotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients", Acta Psychiatr Scand, 76, pp.1~100 (1987)
- Kennedy SH, "A doubleblind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR", J Clin Psychopharmacol, 28, pp.329~333 (2008)
- Komaram RB, "A comparative study of efficacy and safety of agomelatine and escitalopram in major depressive disorder", J Clin Diagn Res, 9, pp.VC05~VC08 (2015)
- Martinotti G, "Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder:a pilot study", J Clin Psychopharmacol, 32, pp.487~491 (2012)
- Kasper S, "Antidepressant efficacy of agomelatine versus SSRI", SNRI: results from a pooled analysis of headto-head studies without a placebo control, 2013, pp.28, 12~19
- Hale A, "Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study", Int Clin Psychopharmacol, 25, pp.305~314 (2010)
- Quera-Salva MA, "Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients", Hum Psychopharmacol, 25, pp.222~229 (2010)
- Lemoine P, "Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine", J Clin Psychiatry, 68, pp.1723~1732 (2007)
- Quera-Salva MA, "Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients", Int Clin Psychopharmacol, 26, pp.252~262 (2011)
- Avila A, "Agomelatine for depression in parkinson disease: additional effect on sleep and motor dysfunction", J Clin Psychopharmacol, 35, pp.719~723 (2015)
- Huang KL, "Comparison of agomelatine and selective serotonin reuptake inhibitors", serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials, 2014, pp.48, 663~671
- Llorca PM, "The antidepressant agomelatine improves thequality of life of depressed patients: implications for remission", J Psychopharmacol, 24, pp.21~26 (2010)
- Stahl SM, "Agomelatine in the treatment of major depressive disorder:an 8-week, multicenter, randomized, placebo-controlled trial", J Clin Psychiatry, 71, pp.616~626 (2010)
- Goodwin GM, "Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, doubleblind, placebo-controlled trial", J Clin Psychiatry, 70, pp.1128~1137 (2009)
- Heun R, "The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study", J Clin Psychiatry, 74, pp.587~594 (2013)
- Gahr M, "Safety and tolerability of agomelatine: focus on hepatotoxicity", Curr Drug Metab, 15, pp.694~702 (2014)